The insider sales are small relative to market cap and are likely driven by tax/estate planning and post-blackout-window liquidity, not a strong bearish signal.
FATE drugs
FATE drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 6 $2.49entry
- T+1 · 3mo ago +12.45%α +11.84% · $2.80
- T+5 · 3mo ago +1.20%α −0.01% · $2.52
- T+20 · 3mo ago −2.81%α −3.41% · $2.42
- T+60 · 18d ago −16.47%α −14.80% · $2.08
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two insiders at Fate Therapeutics, including the CEO, sold a combined $204K worth of shares in open-market transactions on August 4, 2026. While the dollar amount is modest relative to the $303M market cap, multi-executive selling at a struggling biotech with a weak historical follow-through on our calls warrants caution.
Key Financial Metrics
Key Facts
- Two insiders sold a total of 82,747 shares for $204,506 in open-market transactions on Aug 4, 2026.
- President & CEO Bahram Valamehr sold 43,947 shares for $108K; board member Cindy Tahl sold 38,800 shares for $95K.
- This is a cluster of C-suite + board sells, suppressing the typical informational signal of insider sales.
- The total sale value of $204K represents ~0.07% of the $303M market cap, below the 0.1% materiality threshold.
- The company's prior quarterly results and pipeline catalysts are not provided in this filing.
Financial Impact
Total insider selling of $204K represents 0.07% of market cap
Risk Factors
- Post-blackout-window selling often clusters for liquidity reasons, reducing informational value.
- Biotech stocks are driven by pipeline catalysts, not insider activity, this filing contains no clinical or regulatory updates.
- The cluster is small in dollar terms and below typical materiality thresholds for insider selling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-FATE-1786003885323 |
Track record
21 reports on FATE
4 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers